Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Hutchison China MediTech Limited (NASDAQ: HCM).

Full DD Report for HCM

You must become a subscriber to view this report.

Recent News from (NASDAQ: HCM)

Week In Review: Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO
Deals and Financings Hansoh, a Chinese pharma based in Lianyungang, Jiangsu province, has applied to stage an IPO on the Hong Kong exchange. Unlike most companies seeking Hong Kong IPOs, Hansoh is both profitable and established. It claims to be one of the top 30 biopharmas in China, with ...
Source: SeekingAlpha
Date: September, 10 2018 06:09
Your Daily Pharma Scoop: Novocure's Mesothelioma Success, Sangamo's Mixed Results, China's First Homegrown Onco Med
News in focus: NVCR, SGMO Novocure +9.1% after mesothelioma trial shows survival boost Discussion : Novocure ( NVCR ), a midcap biopharma with about $4bn in market capitlization, has seen a tripling of its valuation this year on the back of a slew of positive news. Just about a year a...
Source: SeekingAlpha
Date: September, 06 2018 16:09
Your Cancer Highlight: Chi-Med Looks To Dominate Colorectal Cancer In China
Colorectal cancer ((CRC)) is one of the more difficult and controversial forms of cancer that we face. In America and many parts of Europe, the screening efforts we undertake allow us to catch a lot of cases in the earliest stages, where they can be effectively cured by a pretty simple procedu...
Source: SeekingAlpha
Date: September, 06 2018 08:00
Chi-Med's fruquintinib capsules for previously treated colorectal cancer approved in China
Hutchison China MediTech (NASDAQ: HCM ) announces that fruquintinib capsules have been granted approval for drug registration in China for the treatment of metastatic colorectal cancer (“CRC”) patients, who have failed at least two prior systemic antineoplastic therapies. M...
Source: SeekingAlpha
Date: September, 05 2018 07:20
Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China
– Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate ® – – Elunate ® data published in JAMA demonstrated increased overall survival versus placebo –...
Source: GlobeNewswire
Date: September, 05 2018 02:00


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HCM.

About Hutchison China MediTech Limited (NASDAQ: HCM)

Logo for Hutchison China MediTech Limited (NASDAQ: HCM)

Not available


Contact Information



    Current Share Structure


      Daily Technical Chart for (NASDAQ: HCM)

      Daily Technical Chart for (NASDAQ: HCM)

      Stay tuned for daily updates and more on (NASDAQ: HCM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: HCM)

      Do your DD and if you choose, be ready to go!


      The Research: All source information contained in this email is from the public sources mentioned below.



      Thank you

      DD Report



      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HCM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HCM and does not buy, sell, or trade any shares of HCM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: